secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001140361-24-001416
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports Phase 1 data for ELI-002: 84% T cell response, 16.3-month median RFS
--------------------------------------------------------------------------------

- AMPLIFY-201 data published in Nature Medicine in 25 patients (20 pancreatic, 5 colorectal) with minimal residual mKRAS disease.
- ELI-002 induced direct ex vivo mKRAS-specific T cell responses in 84% of patients; 59% both CD4+ and CD8+.
- 84% of patients had tumor biomarker reduction; 24% achieved complete biomarker clearance.
- Median relapse-free survival was 16.33 months; high T cell responders had 86% reduction in risk of progression or death.
- Phase 2 monotherapy trial in pancreatic ductal adenocarcinoma planned to start early 2024; no safety concerns identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000114036124001416/0001140361-24-001416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000114036124001416/ef20018418_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-001416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer